文献速递白血病MDS 与骨髓增殖性肿瘤

唐氏综合征合并髓系白血病患者的治疗减量:国际ML-DS 2006试验

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
PubMed 文献 · Blood · 2017-04-11

该前瞻性、多中心、开放标签、非随机ML-DS 2006试验纳入170例唐氏综合征相关髓系白血病(ML-DS)患儿,与历史对照相比降低依托泊苷累积剂量并省略维持治疗,5年总生存、无事件生存及复发/无反应累积发生率无显著差异;早期治疗反应差和8号染色体获得为独立预后不良因素。

要点

  • 与历史对照相比,减量治疗未显著影响5年总生存、无事件生存及复发/无反应累积发生率。
  • 早期治疗反应差和8号染色体获得被确定为预测较差无事件生存的独立预后因素。
  • 有细胞遗传学数据的7例复发患者中5例(71%)伴8三体。

核心结论

  • 本研究揭示了ML-DS患儿的预后标志物,并表明减少治疗未损害优异结局。

研究设计与样本

  • 前瞻性、多中心、开放标签、非随机ML-DS 2006试验,由北欧儿科血液肿瘤学会(NOPHO)、荷兰儿童肿瘤学组(DCOG)和急性髓系白血病-柏林-法兰克福-明斯特(AML-BFM)研究组开展,纳入170例ML-DS患儿。

主要发现

  • 与历史对照臂(来自AML-BFM 98试验的ML-DS减强度方案)相比,ML-DS 2006试验降低依托泊苷累积剂量(950降至450 mg/m2)并减少鞘内中枢神经系统预防,同时省略维持治疗。
  • ML-DS 2006试验与历史对照臂的5年总生存率分别为89%±3% vs 90%±4%(Plog-rank=.64),无事件生存率分别为87%±3% vs 89%±4%(Plog-rank=.71),复发/无反应累积发生率分别为6%±3% vs 6%±2%(PGray=.03),均无显著差异。
  • 早期治疗反应差者的5年无事件生存率为58%±16% vs 88%±3%(Plog-rank=.0008)。
  • 8号染色体获得者的复发/无反应累积发生率为16%±7% vs 3%±2%(PGray=.02),5年无事件生存率为73%±8% vs 91%±4%(Plog-rank=.018)。
  • 有细胞遗传学数据的7例复发患者中5例(71%)伴8三体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with myeloid leukemia associated with Down syndrome (ML-DS) have superior outcome compared with non-DS patients, but suffer from higher constitutional cytotoxic drug susceptibility. We analyzed the outcome of 170 pediatric patients with ML-DS enrolled in the prospective, multicenter, open-label, nonrandomized ML-DS 2006 trial by Nordic Society for Pediatric Hematology and Oncology (NOPHO), Dutch Childhood Oncology Group (DCOG), and Acute Myeloid Leukemia-Berlin-Frankfurt-Münster (AML-BFM) study group. Compared with the historical control arm (reduced-intensity protocol for ML-DS patients from the AML-BFM 98 trial), treatment intensity was reduced by lowering the cumulative dose of etoposide (950 to 450 mg/m2) and intrathecal central nervous system prophylaxis while omitting maintenance therapy. Still, 5-year overall survival (89% ± 3% vs 90% ± 4%; Plog-rank = .64), event-free survival (EFS; 87% ± 3% vs 89% ± 4%; Plog-rank = .71), and cumulative incidence of relapse/nonresponse (CIR/NR; 6% ± 3% vs 6% ± 2%; PGray = .03) did not significantly differ between the ML-DS 2006 trial and the historical control arm. Poor early treatment response (5-year EFS, 58% ± 16% vs 88% ± 3%; Plog rank = .0008) and gain of chromosome 8 (CIR/NR, 16% ± 7% vs 3% ± 2%, PGray = .02; 5-year EFS, 73% ± 8% vs 91% ± 4%, Plog rank = .018) were identified as independent prognostic factors predicting a worse EFS. Five of 7 relapsed patients (71%) with cytogenetic data had trisomy 8. Our study reveals prognostic markers for children with ML-DS and illustrates that reducing therapy did not impair excellent outcome. The trial was registered at EudraCT as #2007-006219-2.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Uffmann M, Rasche M, Zimmermann M, et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017. PMID: 28400376. doi:10.1182/blood-2017-01-765057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。